

## Supplementary Online Content

Zaghloul MS, Christodouleas JP, Smith A, et al. Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: a randomized phase 2 trial. *JAMA Surg*. Published online November 29, 2017. doi:10.1001/jamasurg.2017.4591

**eFigure 1.** Schematic of the Clinical Trial Design

**eFigure 2.** Local-Regional Recurrence Free Survival for Chemo+RT vs Chemotherapy Alone for Patients With Urothelial Carcinoma

**eTable 1.** Univariate Analysis of Factors Predictive of Local Recurrence-Free Survival (LRFS)

**eTable 2.** Univariate Analysis of Factors Predictive of Disease-Free Survival (DFS)


**eTable 3.** Univariate Analysis of Factors Predictive of Distant Metastasis-Free Survival (DMFS)

**eTable 4.** Univariate Analysis of Factors Predictive of Overall Survival (OS)


**eTable 5.** Summary Comparison of LRFS, DFS, DMFS, and OS Between the Two Arms (Chemotherapy plus RT vs Chemotherapy Alone)

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure 1.** Schematic of the Clinical Trial Design



**eFigure 2.** Local-Regional Recurrence Free Survival for Chemo+RT vs Chemotherapy Alone for Patients With Urothelial Carcinoma



**eTable 1.** Univariate Analysis of Factors Predictive of Local Recurrence-Free Survival (LRFS)

**Local-regional recurrence-free survival**

Variable	Hazard Ratio	95% confidence interval	<i>p</i> -value
Age	0.96	0.91-1.01	0.09
Female Gender	1.67	0.53-5.26	0.38
Tumor size	1.31	0.97-1.76	0.07
pT stage			
pT2	0.75	0.1-5.84	0.78
pT4	2.29	0.71-7.35	0.16
Grade 3	0.56	0.18-1.76	0.32
Urothelial histology	0.44	0.15-1.28	0.13
Total number of nodes removed	0.90	0.82-0.98	0.02
pN+ disease	0.74	0.25-2.18	0.59
Number of positive nodes at surgery	0.82	0.51-1.31	0.41
Treatment with chemo+RT	0.09	0.02-0.38	<0.01

**eTable 2.** Univariate Analysis of Factors Predictive of Disease-Free Survival (DFS)**Disease-free survival**

<b>Variable</b>	<b>Hazard Ratio</b>	<b>95% confidence interval</b>	<b><i>p</i>-value</b>
Age	0.97	0.94-1.00	0.07
Female Gender	1.30	0.59-2.84	0.52
Tumor size	1.11	0.91-1.35	0.30
pT stage			
pT2	0.26	0.04-1.91	0.19
pT4	1.48	0.68-3.26	0.33
Grade 3	0.80	0.41-1.59	0.53
Urothelial histology	0.75	0.39-1.44	0.39
Total number of nodes removed	1.01	0.95-1.06	0.85
pN+ disease	1.11	0.58-2.13	0.75
Number of positive nodes at surgery	0.99	0.82-1.21	0.94
Treatment with chemo+RT	0.59	0.31-1.12	0.11

**eTable 3.** Univariate Analysis of Factors Predictive of Distant Metastasis-Free Survival (DMFS)

**Distant metastasis-free survival**

Variable	Hazard Ratio	95% confidence interval	<i>p</i> -value
Age	0.96	0.92-1.01	0.09
Female Gender	1.43	0.52-3.9	0.49
Tumor size	0.92	0.7-1.22	0.57
pT stage			
pT4	1.13	0.38-3.37	0.82
Grade 3	0.92	0.37-2.24	0.85
Urothelial histology	0.83	0.35-1.96	0.67
Total number of nodes removed	1.07	1-1.16	0.06
pN+ disease	0.87	0.36-2.11	0.76
Number of positive nodes at surgery	1.04	0.83-1.31	0.73
Treatment with chemo+RT	1.36	0.53-3.52	0.52

**eTable 4.** Univariate Analysis of Factors Predictive of Overall Survival (OS)**Overall survival**

Variable	Hazard Ratio	95% confidence interval	<i>p</i> -value
Age	0.99	0.96-1.02	0.40
Female Gender	1.34	0.68-2.62	0.39
Tumor size	1.03	0.85-1.23	0.78
pT stage			
pT2	0.20	0.03-1.44	0.11
pT4	1.42	0.71-2.86	0.32
Grade 3	1.33	0.75-2.36	0.32
Urothelial histology	0.75	0.43-1.32	0.32
Total number of nodes removed	0.99	0.95-1.04	0.71
pN+ disease	1.11	0.63-1.95	0.72
Number of positive nodes at surgery	0.93	0.76-1.12	0.44
Treatment with chemo+RT	0.68	0.39-1.2	0.18

**eTable 5.** Summary Comparison of LRFS, DFS, DMFS, and OS Between the Two Arms (Chemotherapy plus RT vs Chemotherapy Alone)

Survival Endpoints	Chemo + RT (2 year results)	Chemo alone (2 year results)	Overall Adjusted HR for chemo plus RT vs. chemo alone
Local-regional recurrence free survival	96%	69%	0.08 (95% CI 0.02 – 0.39, $p<0.01$ )
Disease-free survival	68%	56%	0.53 (95% CI 0.27 – 1.06, $p=0.07$ )
Distant metastasis-free survival	73%	79%	1.01 (95% CI 0.37 – 2.76, $p=0.99$ )
Overall survival	71%	60%	0.61 (95% CI 0.33 – 1.11, $p=0.11$ )